SEC Form 4 · accession 0001213900-26-070259
MoonLake Immunotherapeutics · MLTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthias Bodenstedt
Officer — Chief Financial Officer
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 6:45 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001821586
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareF2 | Jun 17, 2026 | S | 15,082 | $19.68 | D | 1,157,349 | D | |
| Class A ordinary shares, par value $0.0001 per shareF3 | Jun 18, 2026 | S | 2,794 | $19.60 | D | 1,154,555 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.